The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | HCC and CCA trials at ESMO 2023: AdvanTIG-206 and ABC-01
Lorenza Rimassa, MD, Humanitas University, Milan, Italy, discusses data from various hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) trials. The Phase II AdvanTIG-206 trial (NCT04948697) of tislelizumab and BAT1706, a bevacizumab biosimilar, with or without ociperlimab in patients with advanced HCC did not show improvement in survival in patients treated with ociperlimab. An analysis of findings from the ABC-01, -02 and -03 trials (NCT00262769, NCT00939848) revealed that patients with extrahepatic CCA fared worse than patents with intrahepatic CCA. Results from a Phase III trial (NCT03654547) of tinengotinib in CCA were additionally discussed, where the novel FGFR2 inhibitor had promising activity and safety. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
